Mark Pegram, MD
Medical Oncology · Stanford, CANPI 1356361554
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $252,414 of the $374,383 with a category attached, or 67.4%. It is spread thinly across 28 manufacturers, the largest accounting for just 23.8%. Among medical oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $1069.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$89K
- Pfizer$50K
- F. Hoffmann-la Roche AG$42K
- Seagen Inc.$39K
- Astrazeneca UK Limited$37K
- Gilead$35K
- plus $83K from 22 others
Across 148 payments — averaging $3753.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$217K
- AstraZeneca$176K
- G1 Therapeutics, Inc.$87K
- Pfizer$67K
- F. Hoffmann-la Roche AG$5K
- Novartis$2K
- plus $2K from 2 others
What the payments were for
- Consulting fees$252,41467%
- Speaking & faculty fees$71,38619%
- Travel & lodging$37,35910%
- Food & beverage$13,2124%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 104 | $89,037 |
| Pfizer(2 entities) | 25 | $49,539 |
| F. Hoffmann-la Roche AG | 17 | $42,065 |
| Seagen Inc. | 31 | $38,614 |
| Astrazeneca UK Limited | 21 | $36,740 |
| Gilead | 42 | $34,975 |
| Novartis | 12 | $19,398 |
| Stemline Therapeutics Inc. | 17 | $16,550 |
| Samsung Bioepis Co., Ltd. | 7 | $8,779 |
| Tersera Therapeutics LLC | 13 | $8,417 |
| Eli Lilly | 19 | $6,574 |
| Sanofi | 1 | $3,645 |
| Cepheid | 2 | $3,076 |
| Athenex Pharmaceutical Division, LLC | 4 | $3,000 |
| Sanofi-aventis U.S. LLC | 2 | $2,552 |
| Daiichi Sankyo Inc. | 3 | $2,194 |
| Philips North America LLC | 2 | $1,900 |
| Macrogenics, Inc. | 1 | $1,500 |
| Blueprint Medicines Corporation | 1 | $1,400 |
| Chugai Pharmaceutical Co., Ltd. | 2 | $1,278 |
| Genentech, Inc. | 4 | $1,025 |
| Halozyme Inc | 1 | $900 |
| Genentech USA, Inc. | 12 | $659 |
| Endomagnetics Ltd | 1 | $227 |
| Puma Biotechnology, Inc. | 3 | $195 |
| Menarini Silicon Biosystems, Inc. | 1 | $74 |
| Leica Microsystems Inc. | 1 | $40 |
| Amgen | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$374,383 in reported general payments places this provider in the 95th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Stanford
- Ronald LevyStanford$475K
- Saad Munib Ahmed KhanStanford$262K
- Sandhya SrinivasStanford$220K
- Joel NealStanford$199K
- Gabriel MannisStanford$171K
- Lipika GoyalStanford$166K
- Melinda TelliStanford$137K
- Ranjana AdvaniStanford$113K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.